1. INTRODUCTION
===============

Prostate cancer is currently the most prevalent form of male cancer in Canada [@b1-co13_3p081]. At diagnosis, 20%--30% of patients will present with advanced or metastatic disease. Of those men, approximately 25% will die from their disease within 2 years [@b2-co13_3p081]. Therapeutic interventions seek not only to increase survival in those patients, but also to improve quality of life ([qol]{.smallcaps}) [@b3-co13_3p081].

The mainstay of treatment for advanced or meta-static prostate cancer is to inhibit the biosynthesis of androgens, the hormones responsible for prostate cancer cell growth. Androgen suppression can be achieved through surgical (bilateral orchiectomy) or medical castration. Medical castration involves the long-term use of luteinizing hormone--releasing hormone ([lhrh]{.smallcaps}) agonists. The two methods of castration appear equally effective in removing testicular androgens [@b4-co13_3p081].

The testes are the major locale for testosterone production; however, the adrenal glands also produce a small but measurable quantity of androgens. It has been hypothesized that removing all circulating androgens---by blocking adrenal androgens in addition to inhibiting testicular androgen production---might be beneficial to patients. Combination treatment, in the form of surgical or medical castration plus administration of an anti-androgen \[for example, flutamide, nilutamide, or cyproterone acetate ([cpa]{.smallcaps})\] is called "maximal androgen blockade" ([mab]{.smallcaps}).

The use of [mab]{.smallcaps} was first introduced in the early 1980s [@b5-co13_3p081]. Since then, a large number of randomized controlled trials have been conducted to evaluate the efficacy of [mab]{.smallcaps} as compared with castration alone. The trials yielded inconsistent results. Most failed to provide convincing evidence of improved survival with [mab]{.smallcaps}; however, a few of the larger trials detected survival benefits with combined treatment [@b6-co13_3p081]--[@b8-co13_3p081]. Low statistical power, study immaturity, compliance to treatment, and imbalances in prognostic indicators between study arms of individual trials were implicated as potential sources of discrepancy [@b9-co13_3p081]--[@b13-co13_3p081].

Recent attempts to determine the treatment efficacy of [mab]{.smallcaps} have involved meta-analyses of the trials [@b14-co13_3p081]. To determine whether [mab]{.smallcaps} is associated with a survival advantage, the present review systematically examines the results of the meta-analyses comparing [mab]{.smallcaps} with castration alone in patients with metastatic prostate cancer.

2. MATERIALS AND METHODS
========================

The present systematic review was originally completed in the context of developing a clinical practice guideline for Cancer Care Ontario's Program in Evidence-Based Care ([pebc]{.smallcaps}), using the methodology of the Practice Guidelines Development Cycle [@b15-co13_3p081]. The literature was searched by one member of [pebc]{.smallcaps}'s Genitourinary Cancer Disease Site Group. Evidence was reviewed and selected by two members, and disagreements pertaining to eligibility were handled through consensus involving the five members of the writing group. Two reviewers assessed eligible reports for important aspects of methodologic quality as expressed in the Quorom statement [@b16-co13_3p081] ([Appendix A](#app1-co13_3p081){ref-type="app"}).

2.1 Literature Search Strategy
------------------------------

We conducted a systematic search of [medline]{.smallcaps} (1980 through July 2004), [embase]{.smallcaps} (1980 through 2004 wk 27), [cancerlit]{.smallcaps} (1980 through October 2002), and the Cochrane Library (2004, Issue 2) databases. In each database, subject headings were combined with disease-specific, treatment-specific, and design-specific search terms ([Appendix B](#app2-co13_3p081){ref-type="app"}). The reference lists of all articles found, including reviews and articles held in personal files, were reviewed for additional citations. The search was restricted to reports published in the English language.

2.2 Eligibility Criteria
------------------------

Published reports or abstracts of meta-analyses comparing [mab]{.smallcaps} (orchiectomy or [lhrh]{.smallcaps} agonist plus administration of an anti-androgen) with castration alone (orchiectomy or [lhrh]{.smallcaps} agonist) in previously untreated men with metastatic prostate cancer (D1 or D2, N+/M0 or M1) were eligible for inclusion. Papers were required to report overall mortality or disease progression-related outcomes, or both. Adverse effects and [qol]{.smallcaps} were also outcomes of interest.

3. RESULTS
==========

3.1 Literature Search Results
-----------------------------

We identified eleven reports representing seven unique meta-analyses [@b17-co13_3p081]--[@b27-co13_3p081]. One meta-analysis was excluded based on language [@b27-co13_3p081], leaving six analyses eligible for inclusion in the review [@b18-co13_3p081],[@b20-co13_3p081],[@b22-co13_3p081]--[@b24-co13_3p081],[@b26-co13_3p081] ([Table I](#ti-co13_3p081){ref-type="table"}). Two meta-analyses pooled individual patient data ([ipd]{.smallcaps}) [@b18-co13_3p081],[@b26-co13_3p081], and four pooled summary data from published trial reports (literature-based) [@b20-co13_3p081],[@b22-co13_3p081]--[@b24-co13_3p081].

### 3.1.2 IPD Meta-analyses

Bertagna *et al.* [@b25-co13_3p081] published the first [ipd]{.smallcaps} meta-analysis in 1994. That analysis was limited to seven double-blind, placebo-controlled trials of [mab]{.smallcaps} with nilutamide (1056 patients). An update published in abstract form by Debruyne *et al.* [@b26-co13_3p081] provided extended follow-up data on survival and disease progression.

In 1995, the Prostate Cancer Trialists' Collaborative Group ([pctcg]{.smallcaps}) published an [ipd]{.smallcaps} meta-analysis that included 22 [mab]{.smallcaps} trials (5710 patients) [@b17-co13_3p081]. All randomized trials that compared castration alone to [mab]{.smallcaps}, both published and unpublished, were sought for inclusion. The main limitations of the report include the absence of explicitly defined eligibility criteria, a description of the methods used to identify and select trials, an appraisal of trial quality and its influence on the pooled results, and an indication of whether subgroup analyses were planned *a priori* ([Appendix A](#app1-co13_3p081){ref-type="app"}). The report is also limited by the fact that overall mortality was the only outcome analyzed; other important endpoints, including toxicity and [qol]{.smallcaps} were not examined. The meta-analysis was updated in 2000 [@b18-co13_3p081] to include a total of twenty-seven trials: twelve used flutamide, eight used nilutamide, and seven used [cpa]{.smallcaps} as the anti-androgen. In combining data on 8725 patients, this updated report represents the most extensive quantitative analysis of [mab]{.smallcaps} trials conducted to date.

### 3.1.3 Literature-based Meta-analyses

The number of trials included in the four literature-based meta-analyses ranged from nine (1978 patients) to twenty (6745 patients; [Table I](#ti-co13_3p081){ref-type="table"}). The largest analysis was conducted for the Agency for Health Care Policy Research ([ahcpr]{.smallcaps}) by Aronson *et al.* [@b20-co13_3p081]. The review was well conducted, with trials systematically identified through a prospectively designed protocol that specified the objectives, literature search strategy, eligibility criteria, method of assessing trial quality, and subgroup and sensitivity analyses, including an assessment of publication bias ([Appendix A](#app1-co13_3p081){ref-type="app"}). Twenty-seven [mab]{.smallcaps} trials were identified, including twelve using flutamide, eight using nilutamide, and seven using [cpa]{.smallcaps}. Overall mortality was the only outcome for which data were statistically pooled, but data on disease progression, [qol]{.smallcaps}, and adverse effects were also summarized.

The three other literature-based meta-analyses were restricted in scope, analyzing trials that compared castration with [mab]{.smallcaps} using nonsteroidal anti-androgens ([nsaa]{.smallcaps}) [@b22-co13_3p081]--[@b24-co13_3p081]. The largest of those analyses, carried out by Schmitt *et al.* [@b22-co13_3p081] for the Cochrane Prostatic Diseases and Urologic Cancers Group, included twenty trials and pooled data on overall mortality, progression-free survival ([pfs]{.smallcaps}), and cancer-specific survival. Bennett *et al.* [@b23-co13_3p081] and Caubet *et al.* [@b24-co13_3p081] both included nine trials and pooled data on overall mortality [@b23-co13_3p081],[@b24-co13_3p081] and [pfs]{.smallcaps} [@b24-co13_3p081].

3.2 Outcomes
------------

### 3.2.1 Overall Survival

#### IPD Meta-analyses

Results from the original [pctcg]{.smallcaps} overview showed a small survival benefit with [mab]{.smallcaps} that was not statistically significant (5-year survival: 22.8% vs. 26.2%; *p* \> 0.1) [@b17-co13_3p081]. In the updated meta-analysis (2000), the [pctcg]{.smallcaps} reported a nonsignificant overall hazard ratio ([hr]{.smallcaps}) of 0.96 \[95% confidence interval ([ci]{.smallcaps}): 0.91--1.01; *p* = 0.11\], where ratios less than 1 favoured [mab]{.smallcaps} [@b18-co13_3p081] ([Table II](#tii-co13_3p081){ref-type="table"}). Further analyses at different follow-up periods also showed no difference in mortality and suggested an absolute 5-year survival difference of approximately 2% in favour of [mab]{.smallcaps}. Subgroup analyses were performed by method of androgen suppression (orchiectomy vs. [lhrh]{.smallcaps} agonist), type of anti-androgen, patient age, stage of disease (metastases vs. no metastases), and non--prostate cancer mortality. With the exception of type of anti-androgen, no significant differences in treatment effect were observed within any of those subgroups. A small and statistically significant survival benefit was detected for [mab]{.smallcaps} with flutamide ([hr]{.smallcaps} = 0.92; 95% [ci]{.smallcaps}: 0.86--0.98; *p* = 0.02), and a similar but nonsignificant result was observed for nilutamide. [mab]{.smallcaps} with [cpa]{.smallcaps} was associated with a significantly worse survival outcome than castration alone ([hr]{.smallcaps} = 1.13; 95% [ci]{.smallcaps}: 1.01--1.25; *p* = 0.04). Treatment with [mab]{.smallcaps} containing either of the [nsaa]{.smallcaps}s increased 5-year survival over castration alone by 3% (27.6% vs. 24.7%, *p* = 0.005).

Debruyne *et al.* [@b26-co13_3p081] reported a reduction in the odds of death in patients treated with nilutamide-containing [mab; mab]{.smallcaps} was associated with a 16% reduction in mortality as compared with castration alone \[odds ratio ([or]{.smallcaps}) = 0.84; 95% [ci]{.smallcaps}: 0.71--0.99; *p* = 0.038\].

#### Literature-based Meta-analyses

[Table III](#tiii-co13_3p081){ref-type="table"} summarizes the results for overall mortality from the four literature-based meta-analyses. Aronson *et al.* [@b20-co13_3p081] detected no significant difference in overall mortality at 2 years, although at 5 years, overall mortality was significantly improved with [mab]{.smallcaps} ([hr]{.smallcaps} = 0.87; 95% [ci]{.smallcaps}: 0.81--0.94). However, the 5-year estimate was based on half the trials (10 trials, 66% of patients) that contributed to the 2-year estimate. No differences in treatment effect were detected in any of the subgroup analyses performed (method of androgen suppression, stage of disease, type of anti-androgen, or trial quality).

Schmitt *et al.* [@b22-co13_3p081] reported no difference in mortality at 1 or 2 years between [nsaa mab]{.smallcaps} and castration-only arms, but 5-year mortality was better with [mab]{.smallcaps} ([or]{.smallcaps} = 1.29; 95% [ci]{.smallcaps}: 1.11--1.50; *p* = 0.0009). The two other literature-based reports examining [nsaa mab]{.smallcaps} detected significant reductions in the risk for mortality with [mab]{.smallcaps} that ranged between 10% and 22% [@b23-co13_3p081],[@b24-co13_3p081].

### 3.2.2 Disease Progression

Pooled analyses of disease progression data were available from three of the six meta-analyses [@b22-co13_3p081],[@b24-co13_3p081],[@b26-co13_3p081]; however, those analyses are limited by the inclusion of a small proportion of [mab]{.smallcaps} trials. Each of those reports combined data from trials of [mab]{.smallcaps} using [nsaa]{.smallcaps}. Debruyne *et al.* [@b26-co13_3p081] reported that, among seven trials, the odds of progression were reduced by 17% by [mab]{.smallcaps} with nilutamide ([or]{.smallcaps} = 0.83; 95% [ci]{.smallcaps}: 0.70--0.98; *p* = 0.031). Schmitt *et al.* [@b22-co13_3p081]pooled published [pfs]{.smallcaps} data at 1 (seven trials), 2 (five trials), and 5 years (two trials); the odds of progression were significantly reduced with [mab]{.smallcaps} at 1 year ([or]{.smallcaps} = 1.38; 95% [ci]{.smallcaps}: 1.15--1.67; *p* = 0.0006), but not at 2 or 5 years. Caubet *et al.* [@b24-co13_3p081] reported a 23%--26% reduction in the risk for progression with [mab]{.smallcaps} depending on the type of meta-analytic method used \[relative risk ([rr]{.smallcaps}) = 0.74, *p* \< 0.001 among seven trials; [rr]{.smallcaps} = 0.77, *p* \< 0.001 among seven trials\].

A more representative presentation of disease progression data was provided by Aronson *et al.* [@b20-co13_3p081]. They summarized twenty-three trials [@b6-co13_3p081],[@b8-co13_3p081],[@b29-co13_3p081],[@b30-co13_3p081],[@b32-co13_3p081],[@b36-co13_3p081],[@b38-co13_3p081]--[@b40-co13_3p081],[@b42-co13_3p081],[@b43-co13_3p081],[@b46-co13_3p081]--[@b49-co13_3p081],[@b53-co13_3p081]--[@b58-co13_3p081],[@b60-co13_3p081] reporting those data. Nineteen of the trials reported no significant difference between [mab]{.smallcaps} and castration alone on those measures [@b29-co13_3p081],[@b30-co13_3p081],[@b32-co13_3p081],[@b36-co13_3p081],[@b38-co13_3p081]--[@b40-co13_3p081],[@b42-co13_3p081],[@b43-co13_3p081],[@b46-co13_3p081]--[@b49-co13_3p081],[@b54-co13_3p081]--[@b58-co13_3p081],[@b60-co13_3p081]. Among six trials reporting [pfs]{.smallcaps} [@b6-co13_3p081],[@b8-co13_3p081],[@b29-co13_3p081],[@b32-co13_3p081],[@b36-co13_3p081],[@b47-co13_3p081], two reported a statistically significant longer progression-free interval with [mab]{.smallcaps} [@b6-co13_3p081],[@b8-co13_3p081]. Both of those trials used an [nsaa]{.smallcaps} in the [mab]{.smallcaps} arm. One trial compared orchiectomy plus placebo with orchiectomy plus nilutamide (median [pfs]{.smallcaps}: 15 months vs. 21 months; *p* = 0.002) [@b8-co13_3p081], and the other compared leuprolide plus placebo with leuprolide plus flutamide (median [pfs]{.smallcaps}: 14 months vs. 17 months; *p* = 0.039) [@b6-co13_3p081].Of the seventeen trials that reported on time-to-disease progression ([ttp]{.smallcaps}) [@b4-co13_3p081],[@b30-co13_3p081],[@b38-co13_3p081]--[@b40-co13_3p081],[@b42-co13_3p081],[@b43-co13_3p081],[@b46-co13_3p081],[@b48-co13_3p081],[@b49-co13_3p081], [@b54-co13_3p081]--[@b56-co13_3p081],[@b58-co13_3p081],[@b60-co13_3p081], one trial comparing orchiectomy with goserelin plus flutamide detected a significantly longer [ttp]{.smallcaps} interval with [mab]{.smallcaps} (median [ttp]{.smallcaps}: 18 months vs. 12 months; *p* = 0.002) [@b4-co13_3p081].

### 3.2.3 QOL and Adverse Effects

Aronson *et al.* [@b20-co13_3p081] wrote the only report that reviewed [qol]{.smallcaps} and adverse effects. Among the 27 randomized controlled trials that those authors reviewed, only one formally assessed [qol]{.smallcaps}. The authors summarized two reports [@b61-co13_3p081],[@b62-co13_3p081] of the large National Cancer Institute ([nci]{.smallcaps}) [int]{.smallcaps}-0105 Southwest Oncology Group/Eastern Cooperative Oncology Group trial [@b29-co13_3p081], which compared orchiectomy plus flutamide with orchiectomy plus placebo. Measures of [qol]{.smallcaps} included three treatment-related symptoms (diarrhea, gas pain, and body image), physical functioning, and emotional functioning; all were assessed at 1, 3, and 6 months after the start of treatment. Patients treated with [mab]{.smallcaps} experienced significantly more diarrhea at 3 months (*p* \< 0.001) and worse emotional functioning at 3 and 6 months (*p* \< 0.003) than did patients treated with castration alone. Nonsignificant trends toward poor scores on measures of physical functioning, fatigue, abdominal gas, overall pain, and body image were also observed with [mab]{.smallcaps}.

Major limitations were present in the reporting of adverse effects in the [mab]{.smallcaps} trials. Because of those limitations, data on adverse effects were supplemented with similar data from package inserts that accompany therapeutic agents marketed in the United States and from phase [ii]{.smallcaps} studies. [Tables IV](#tiv-co13_3p081){ref-type="table"} and [V](#tv-co13_3p081){ref-type="table"} summarize the adverse effects data contained in the Aronson *et al.* report [@b20-co13_3p081]. Compared with castration alone, treatment with [mab]{.smallcaps} that included [nsaa]{.smallcaps} appeared to produce more gastrointestinal-related problems and more frequent withdrawal from treatment. When [mab]{.smallcaps} contained [cpa]{.smallcaps}, treatment was associated with more complications related to endocrine function, but a withdrawal pattern similar to that in patients receiving monotherapy was demonstrated.

4. DISCUSSION
=============

Six meta-analyses form the evidence base of the present review [@b17-co13_3p081],[@b18-co13_3p081],[@b20-co13_3p081],[@b22-co13_3p081]--[@b25-co13_3p081]. Evidence from those analyses suggests that patient outcomes depend on the type of anti-androgen used with [mab]{.smallcaps}. The [pctcg]{.smallcaps} meta-analysis [@b18-co13_3p081] showed that [mab]{.smallcaps} was not associated with a statistically significant improvement in overall survival. However, when outcomes were analyzed by type of anti-androgen, varying treatment efficacies among the agents were evident. Small but statistically significant survival benefits in the range of 3% at 5 years were detected among trials that used [mab]{.smallcaps} with an [nsaa]{.smallcaps} (as compared with castration alone). Compared with castration alone, [mab]{.smallcaps} with [cpa]{.smallcaps} (a steroidal anti-androgen) was associated with an approximate 3% increased risk of death.

Variability in the magnitude of outcome among meta-analyses may arise from a number of factors, including the number and size of the trials contributing to the pooled estimate, the type of anti-androgens being evaluated, and the use of published summary data or [ipd]{.smallcaps} for the analyses. The four literature-based meta-analyses [@b20-co13_3p081],[@b22-co13_3p081]--[@b24-co13_3p081] included fewer trials (and fewer patients) than did the [pctcg]{.smallcaps} meta-analysis, but the resulting pooled estimates were of greater magnitude (in favour of [mab]{.smallcaps}) than were those generated using [ipd]{.smallcaps} [@b18-co13_3p081]. In meta-analyses based on published data, publication bias is more likely to exaggerate treatment effects [@b63-co13_3p081]. Only one of the four literature-based meta-analyses assessed the influence of publication status on the overall pooled result [@b20-co13_3p081]. With [ipd]{.smallcaps}, many of the problems associated with published data that introduce bias are eliminated by the ability to incorporate all trial data (published and unpublished), to check the integrity of patient randomization, and to perform proper time-to-event analyses (as compared with fixed time point) by intent-to-treat [@b64-co13_3p081],[@b65-co13_3p081]. Further, because of greater patient numbers, [ipd]{.smallcaps} often provides greater statistical power to properly perform subgroup analyses [@b65-co13_3p081]. The methodologic weaknesses of the [pctcg]{.smallcaps} have been identified, but the advantages of using [ipd]{.smallcaps} currently make the [pctcg]{.smallcaps} meta-analysis the most reliable evidence comparing [mab]{.smallcaps} with castration alone.

To decide whether [mab]{.smallcaps} should be the preferred treatment for patients, the small survival benefit and the additional adverse effects of combined treatment must be balanced. The clinical significance of a statistically significant 3% improvement in survival with [nsaa mab]{.smallcaps} is questionable, especially when the toxicity of [mab]{.smallcaps} is considered. Data on adverse effects and [qol]{.smallcaps} are limited, but they suggest increased toxicity and a concomitant decline in [qol]{.smallcaps} in [mab]{.smallcaps}-treated patients. In addition, data on disease progression provide further evidence that [mab]{.smallcaps} does not provide superior treatment efficacy over castration alone [@b20-co13_3p081].

Based on the evidence reviewed, [mab]{.smallcaps} should not be routinely offered to patients with metastatic prostate cancer. Monotherapy, consisting of orchiectomy or the administration of an [lhrh]{.smallcaps} agonist, should be recommended as standard treatment.

It is important to distinguish between [mab]{.smallcaps} as long-term treatment and short-term use of [mab]{.smallcaps} in the prevention of testosterone flare. In patients treated with medical castration, initial treatment with an [lhrh]{.smallcaps} agonist is accompanied by a surge in serum testosterone during the first week or weeks of therapy, followed by a decline. That surge may exacerbate existing metastatic disease [@b66-co13_3p081],[@b67-co13_3p081],[@b68-co13_3p081], therefore short-term use of an anti-androgen is indicated to prevent or block the flare phenomenon [@b68-co13_3p081]. Administration of an anti-androgen is reasonable for a period of 2--4 weeks when treatment with an [lhrh]{.smallcaps} agonist is initiated.

Because of the small survival improvement observed with [mab]{.smallcaps}, some clinicians may still choose [mab]{.smallcaps} over monotherapy for individual patients. If [mab]{.smallcaps} is administered with this intent, [mab]{.smallcaps} containing a [nsaa]{.smallcaps} is suggested. Given its higher mortality, [mab]{.smallcaps} with [cpa]{.smallcaps} should be avoided as compared with castration alone [@b18-co13_3p081].

The present review did not identify any meta-analyses that included trials evaluating [mab]{.smallcaps} with the newer anti-androgen bicalutamide. Bicalutamide-based [mab]{.smallcaps} has been compared in a randomized trial only with combination flutamide [@b69-co13_3p081]. A castration-only control arm was deemed unethical at the time the bicalutamide trial was designed because [mab]{.smallcaps} was considered standard care (over monotherapy). The trial compared bicalutamide plus an [lhrh]{.smallcaps} agonist with flutamide plus an [lhrh]{.smallcaps} agonist and detected a survival improvement with bicalutamide that was not statistically significant (median survival: 180 weeks vs. 148 weeks; [hr]{.smallcaps} = 0.87; 95% [ci]{.smallcaps}: 0.72--1.05; *p* = 0.15) [@b69-co13_3p081]. With the exception of a higher incidence of hematuria, bicalutamide appeared less toxic than flutamide. Klotz *et al.* [@b70-co13_3p081] recently re-analyzed the data from the bicalutamide trial [@b69-co13_3p081] and the [pctcg]{.smallcaps} meta-analysis (subgroup of trials comparing [mab]{.smallcaps} with flutamide versus castration alone) [@b18-co13_3p081] to calculate an estimate of the likely benefit of [mab]{.smallcaps} with bicalutamide relative to castration alone. They reported an estimated [hr]{.smallcaps} of 0.80 (95% [ci]{.smallcaps}: 0.66--0.98) for bicalutamide-based [mab]{.smallcaps} versus castration alone, which equates to a 20% relative reduction in the risk of death with bicalutamide. On the basis of those data, use of bicalutamide in patients who are offered [mab]{.smallcaps} would also be reasonable. A randomized trial comparing [mab]{.smallcaps} with bicalutamide to castration alone is ongoing, but that trial is assessing bicalutamide at a dose of 80 mg [@b71-co13_3p081]. Before beginning [mab]{.smallcaps}, selected patients should be advised of the magnitude of the survival benefit and on possible adverse effects and their potential impact on [qol]{.smallcaps}.

Progressive prostate cancer is usually detected through a rise in prostate-specific antigen ([psa]{.smallcaps}), which usually predates clinical or radiologic evidence of metastases. Most patients included in [mab]{.smallcaps} trials had documented metastases (stage D2), and whether results from those trials are generalizable to patients with a rising [psa]{.smallcaps} without evidence of metastatic disease is unknown. Only a handful of trials have analyzed outcomes by extent of meta-static involvement [@b4-co13_3p081],[@b6-co13_3p081],[@b11-co13_3p081],[@b29-co13_3p081],[@b34-co13_3p081]. Most of those have not shown a benefit of [mab]{.smallcaps} in patients with minimal disease, although the subgroup analyses included small numbers of patients. Only 12% of patients (approximately 1000) in the [pctcg]{.smallcaps} meta-analysis [@b18-co13_3p081] had documented non-metastatic prostate cancer. An analysis of those patients showed slightly worse survival with [mab]{.smallcaps}, although the difference did not reach statistical significance. Prospective randomized trials to investigate the efficacy of [mab]{.smallcaps} in that subgroup of patients are warranted.

5. CONCLUSIONS
==============

The small survival benefit conferred by [mab]{.smallcaps} with [nsaa]{.smallcaps} is of questionable clinical significance given the added toxicity and concomitant decline in [qol]{.smallcaps} observed in patients treated with [mab]{.smallcaps}. Therefore, combined treatment with flutamide or nilutamide should not be routinely offered to patients with metastatic prostate cancer (beyond the purpose of blocking testosterone flare). Monotherapy consisting of orchiectomy or the administration of a [lhrh]{.smallcaps} agonist is recommended as standard treatment.

Figures and Tables
==================

###### 

Meta-analyses identified by the literature search---descriptions

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                       *Trials included in meta-analysis:[mab]{.smallcaps}with*                                                                                                        
  ---------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------
  Individual patient data ([ipd]{.smallcaps}) meta-analyses                                                                                                                                                                                                            

   [pctcg]{.smallcaps} 2000 [@b18-co13_3p081]                                                          Bono ([ilg]{.smallcaps} ), 1998[@b28-co13_3p081]                                                     Dijkman ([iasg]{.smallcaps}), 1997[@b8-co13_3p081]         De Voogt ([eortc]{.smallcaps}), 1998[@b44-co13_3p081]

    31 [rct]{.smallcaps}s included in review                                                           Denis ([eortc]{.smallcaps}), 1998 [@b7-co13_3p081]                                                   Bertagna, 1994[@b25-co13_3p081]                            Theiss, 1996[@b45-co13_3p081]

    27 [rct]{.smallcaps}s provided [ipd]{.smallcaps} for meta-analysis                                 Eisenberger ([nci]{.smallcaps}/[swog]{.smallcaps}), 1998 [@b29-co13_3p081]                           Béland ([casg]{.smallcaps}), 1990[@b38-co13_3p081]         Thorpe, 1996[@b46-co13_3p081]

     12 flutamide trials                                                                               Ferrari (Italy), 1996[@b30-co13_3p081]                                                               Crawford, 1990[@b39-co13_3p081]                            Robinson ([eortc]{.smallcaps}), 1995[@b47-co13_3p081]

     8 nilutamide trials                                                                               Zalcberg (Australia), 1996 [@b31-co13_3p081]                                                         Namer, 1990[@b40-co13_3p081]                               Jorgensen ([spcg]{.smallcaps} ), 1993[@b48-co13_3p081]

     7 [cpa]{.smallcaps} trials                                                                        Boccardo ([poncap]{.smallcaps}), 1993[@b32-co13_3p081]                                               Knonagel, 1989[@b41-co13_3p081]                            DiSilverio (Italy), 1990[@b49-co13_3p081]

    88% of patients staged "metastatic";                                                               Fourcade (France), 1993 [@b33-co13_3p081]                                                            Brisset, 1987 [@b42-co13_3p081]                            

     12% staged "locally advanced"                                                                     Iversen ([daproca]{.smallcaps}), 1993 [@b34-co13_3p081]\                                             Navratil, 1987 [@b43-co13_3p081]                           
                                                                                                       Tyrrell ([ipcsg]{.smallcaps} ), 1993 [@b35-co13_3p081]\                                                                                                         
                                                                                                       Crawford ([nci]{.smallcaps}), 1989[@b6-co13_3p081]\                                                                                                             
                                                                                                       Schulze ([wpsg]{.smallcaps}), 1988 [@b36-co13_3p081]\                                                                                                           
                                                                                                       Delaere, 1987 [@b37-co13_3p081]                                                                                                                                 

   Bertagna 1994 [@b25-co13_3p081], Debruyne 1996 [@b26-co13_3p081]                                    None                                                                                                 Bertagna, 1994 [@b25-co13_3p081]                           None

    Included 7 double-blind [rct]{.smallcaps}s                                                                                                                                                              Janknegt ([iasg]{.smallcaps}), 1993[@b50-co13_3p081]       

    7 nilutamide trials                                                                                                                                                                                     Brisset, 1990 [@b51-co13_3p081]                            

    % of patients staged D not reported                                                                                                                                                                     Namer, 1990 [@b40-co13_3p081]\                             
                                                                                                                                                                                                            Knonagel, 1989 [@b41-co13_3p081]\                          
                                                                                                                                                                                                            Béland ([casg]{.smallcaps}), 1988 [@b52-co13_3p081]        

  Literature-based meta-analyses                                                                                                                                                                                                                                       

   Schmitt 2003 [@b22-co13_3p081]                                                                      Bono ([ilg]{.smallcaps}), 1998[@b28-co13_3p081]                                                      Dijkman ([iasg]{.smallcaps}), 1997[@b8-co13_3p081]         None

    20 [rct]{.smallcaps}s included in review                                                           Eisenberger ([nci]{.smallcaps}/[swog]{.smallcaps}/[int]{.smallcaps}- 1015), 1998 [@b29-co13_3p081]   Béland ([casg]{.smallcaps}), 1990[@b38-co13_3p081]         

    14 [rct]{.smallcaps}s provided data for meta-analysis [a](#tfn1-co13_3p081){ref-type="table-fn"}                                                                                                        Crawford, 1990 [@b39-co13_3p081]                           

     9 flutamide trials                                                                                Zalcberg (Australia), 1996 [@b31-co13_3p081]                                                         Namer (France), 1990 [@b40-co13_3p081]                     

     5 nilutamide trials                                                                               Boccardo ([poncap]{.smallcaps}), 1993 [@b32-co13_3p081]                                              Brisset, 1987 [@b42-co13_3p081]                            

    96% of patients were stage D2 or M1                                                                Denis ([eortc]{.smallcaps}), 1993[@b53-co13_3p081]                                                   Tyrrell ([ipcsg]{.smallcaps}), 1991[@b54-co13_3p081]\      
                                                                                                                                                                                                            Fourcade (France), 1990 [@b55-co13_3p081]\                 
                                                                                                                                                                                                            Iversen ([daproca]{.smallcaps}), 1990 [@b56-co13_3p081]\   
                                                                                                                                                                                                            Crawford ([nci]{.smallcaps}), 1989 [@b6-co13_3p081]        

   Aronson 1999[@b20-co13_3p081]                                                                       Same as above                                                                                        Same as above                                              Robinson ([eortc]{.smallcaps}), 1995[@b47-co13_3p081]

    27 [rct]{.smallcaps}s included in review                                                                                                                                                                                                                           Jorgensen ([spcg]{.smallcaps}), 1993 [@b48-co13_3p081]

    20 [rct]{.smallcaps}s provided data for meta-analysis                                                                                                                                                                                                              DeVoogt ([eortc]{.smallcaps} ), 1990[@b57-co13_3p081]

     9 flutamide trials                                                                                                                                                                                                                                                DiSilverio (Italy), 1990 [@b49-co13_3p081]

     5 nilutamide trials                                                                                                                                                                                                                                               Williams (U.K.), 1990 [@b58-co13_3p081]

     6 [cpa]{.smallcaps} trials                                                                                                                                                                                                                                        Klosterhalfen, 1987 [@b59-co13_3p081]

    93% of patients were stage D2                                                                                                                                                                                                                                      

   Bennet 1999 [@b23-co13_3p081]                                                                       Eisenberger ([nci]{.smallcaps}/[swog]{.smallcaps}), 1998[@b29-co13_3p081]                            None                                                       None

    9 [rct]{.smallcaps}s included in review                                                            Zalcberg (Australia), 1996[@b31-co13_3p081]                                                                                                                     

    9 [rct]{.smallcaps}s provided data for meta-analysis                                               Boccardo ([poncap]{.smallcaps}), 1993[@b32-co13_3p081]                                                                                                          

     9 flutamide trials                                                                                Denis ([eortc]{.smallcaps}), 1993 [@b4-co13_3p081]                                                                                                              

    98% of patients were stage D                                                                       Fourcade (France), 1993 [@b33-co13_3p081]\                                                                                                                      
                                                                                                       Tyrrell ([ipcsg]{.smallcaps}), 1991 [@b54-co13_3p081]\                                                                                                          
                                                                                                       Iversen ([daproca]{.smallcaps}), 1990 [@b56-co13_3p081]\                                                                                                        
                                                                                                       Crawford ([nci]{.smallcaps}), 1989[@b6-co13_3p081]\                                                                                                             
                                                                                                       Schulze ([wpsg]{.smallcaps}), 1988 [@b36-co13_3p081]                                                                                                            

   Caubet 1997 [@b24-co13_3p081]                                                                       Boccardo ([poncap]{.smallcaps}), 1993[@b32-co13_3p081]                                               Janknegt ([iasg]{.smallcaps}), 1993[@b50-co13_3p081]       None

    13 [rct]{.smallcaps}s included in review                                                           Denis ([eortc]{.smallcaps}), 1993 [@b4-co13_3p081]                                                   Béland ([casg]{.smallcaps}), 1991[@b38-co13_3p081]         

    9 [rct]{.smallcaps}s provided data for meta-analysis                                               Iversen ([daproca]{.smallcaps}), 1993 [@b34-co13_3p081]                                              Navratil, 1987[@b43-co13_3p081]                            

     6 flutamide trials                                                                                Tyrrell ([ipcsg]{.smallcaps}), 1993 [@b35-co13_3p081]                                                                                                           

     3 nilutamide trials                                                                               Crawford ([nci]{.smallcaps}), 1989[@b6-co13_3p081]                                                                                                              

    57%--100% of patients staged D2                                                                    Schulze ([wpsg]{.smallcaps}), 1988 [@b36-co13_3p081]                                                                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The 14 trials listed in [Table I](#ti-co13_3p081){ref-type="table"} contributed to the pooled analysis of 2-year survival data. Thirteen trials [@b6-co13_3p081],[@b8-co13_3p081],[@b28-co13_3p081],[@b29-co13_3p081],[@b31-co13_3p081],[@b32-co13_3p081],[@b34-co13_3p081],[@b38-co13_3p081],[@b40-co13_3p081],[@b42-co13_3p081],[@b53-co13_3p081]--[@b55-co13_3p081] and seven trials [@b6-co13_3p081],[@b8-co13_3p081],[@b28-co13_3p081],[@b29-co13_3p081],[@b34-co13_3p081],[@b53-co13_3p081],[@b54-co13_3p081] contributed to the pooled analysis of 1-year and 5-year survival data, respectively.

[mab]{.smallcaps} = maximal androgen blockade; [cpa]{.smallcaps} = cyproterone acetate; [pctcg]{.smallcaps} = Prostate Cancer Trialists' Collaborative Group; [rct]{.smallcaps}s = randomized controlled trials; [ilg]{.smallcaps} = Italian Leuprorelin Group; [eortc]{.smallcaps} = European Organization for Research and Treatment of Cancer; [nci]{.smallcaps} = National Cancer Institute; [swog]{.smallcaps} = Southwest Oncology Group; [poncap]{.smallcaps} = Italian Prostatic Cancer Project; [daproca]{.smallcaps} = Danish Prostatic Cancer Group; [ipcsg]{.smallcaps} = International Prostate Cancer Study Group; [wpsg]{.smallcaps} = Westfälische Prostatakarzinom Study Group; [iasg]{.smallcaps} = International Anandron Study Group; [casg]{.smallcaps} = Canadian Anandron Study Group; [spcg]{.smallcaps} = Scandinavian Prostatic Cancer Group.

###### 

Results (mortality for maximal androgen blockade vs. castration alone ^a^) from the 2000 Prostate Cancer Trialists' Collaborative Group individual patient data meta-analysis

  ------------------------------------------------------------------------------------------------------------------
                                                       *Estimated[hr]{.smallcaps}(95%[ci]{.smallcaps}),* p *value*
  ---------------------------------------------------- -------------------------------------------------------------
  Overall mortality (*n=*8725)                         0.96 (0.91--1.01), 0.11

   By years since randomization:                       

    Year 0                                             1.01 (0.91--1.11), [nr]{.smallcaps}

    Years 1--2                                         0.93 (0.85--1.01), [nr]{.smallcaps}

    Years 3--4                                         0.97 (0.85--1.09), [nr]{.smallcaps}

    Year 5 onward                                      0.94 (0.76--1.12), [nr]{.smallcaps}\
                                                       5-Year survival estimates:\
                                                       25.4% vs. 23.6%, *p\>*0.1

  Subgroup analyses                                    

   Age                                                 

    \<65 (*n=*1641)                                    0.90 (0.78--1.02), [nr]{.smallcaps}

    65--74 (*n=*3094)                                  0.96 (0.88--1.04), [nr]{.smallcaps}

    ≥75 (*n=*2487)                                     0.95 (0.85--1.05), [nr]{.smallcaps}

   Stage of disease                                    

    Definite metastases (*n=*7190)                     0.95 (0.89--1.01), [nr]{.smallcaps}

    No metastases (*n=*1025)                           1.06 (0.86--1.30), [nr]{.smallcaps}

   Non-prostate cancer mortality (*n=*4876)            1.04 (0.88--1.20), 0.7

   Type of anti-androgen                               

    Flutamide (*n=*4803)                               0.92 (0.86--0.98), 0.02

    Nilutamide (*n=*1751)                              0.92 (0.80--1.04), \>0.1

    [cpa]{.smallcaps} (*n=*1661)                       1.13 (1.01--1.25), 0.04

   Class of anti-androgen                              5-Year survival estimates:

    Non-steroidal (flutamide + nilutamide; *n=*6500)   27.6% vs. 24.7%, *p=*0.005

    Steroidal ([cpa]{.smallcaps}; *n=*1800)            15.4% vs. 18.1%, *p=*0.04
  ------------------------------------------------------------------------------------------------------------------

[hr]{.smallcaps} = hazard ratio; [ci]{.smallcaps} = confidence interval; [nr]{.smallcaps} = not reported; [cpa]{.smallcaps} = cyproterone acetate.

###### 

Results from literature-based meta-analyses of maximal androgen blockade ([mab]{.smallcaps})

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Meta-analysis*                                                                                                       *Mortality results \[estimated*[hr]{.smallcaps}*(95%[ci]{.smallcaps}),* p *value\]*                                                                                                                                         
  --------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------
  [mab]{.smallcaps} with any anti-androgen vs. castration alone [a](#tfn4-co13_3p081){ref-type="table-fn"}                                                                                                                                                                                                                                          

   Aronson 1999 [@b20-co13_3p081]                                                                                                                                                                                                            2-year (20 trials, 6745 patients) 0.97 (0.87--1.09), [nr]{.smallcaps}                                  5-year (10 trials, 4443 patients) 0.87 (0.81--0.94), [nr]{.smallcaps}

  [mab]{.smallcaps} with non-steroidal anti-androgens vs. castration alone [a](#tfn4-co13_3p081){ref-type="table-fn"}                                                                                                                                                                                                                               

   Schmitt 2003 [@b22-co13_3p081]                                                                                       1-year (13 trials, 4970 patients) 1.03 [b](#tfn5-co13_3p081){ref-type="table-fn"} (0.85--1.25), 0.7                  2-year (14 trials, 5286 patients) 1.14 [b](#tfn5-co13_3p081){ref-type="table-fn"} (1.00--1.31), 0.06   5-year (7 trials, 3550 patients) 1.29 [b](#tfn5-co13_3p081){ref-type="table-fn"} (1.11--1.50), 0.0009

   Bennet 1999[@b23-co13_3p081]                                                                                         Overall (9 trials, 4128 patients) 0.90 (0.79--1.00), [nr]{.smallcaps}                                                                                                                                                       

   Caubet 1997 [@b24-co13_3p081]                                                                                        Overall: Method 1 [c](#tfn6-co13_3p081){ref-type="table-fn"} (7 trials, 1978 patients) 0.78 (0.67--0.90), \<0.001\                                                                                                          
                                                                                                                        Overall: Method 2 [c](#tfn6-co13_3p081){ref-type="table-fn"} (7 trials, 2592 patients) 0.84 (0.76--0.93), \<0.001                                                                                                           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Unless otherwise specified, summary statistic values less than 1 favour [mab]{.smallcaps} and values greater than 1 favour castration alone.

Odds ratio. A ratio greater than 1 favours [mab]{.smallcaps}; a ratio less than 1 favours castration alone.

Method 1: Hazard ratios were derived by reconstructing annual life tables from survival curves and fitting discrete proportional hazard models. Method 2: Hazard ratios were derived from reported *p* values and numbers of deaths.

[hr]{.smallcaps} = hazard ratio; [ci]{.smallcaps} = confidence interval; [nr]{.smallcaps} = not reported.

###### 

Adverse effects by category, combined results

                                        *Castration only*   *[mab]{.smallcaps}: Castration +[nsaa]{.smallcaps}*   *[mab]{.smallcaps}: Castration +[cpa]{.smallcaps}*   *Any[mab]{.smallcaps}*                                             
  ------------------------------------- ------------------- ----------------------------------------------------- ---------------------------------------------------- ------------------------ ------------------ --- ------------------ ----
  Cardiovascular                                                                                                                                                                                                                          
   Cardiovascular, not specified        570 (4)             4                                                     387 (4.9)                                            3                        175 (1.7)          1   562 (3.9)          4
   Edema                                569 (3.2)           3                                                     293 (2)                                              1                        277 (6.5)          2   570 (4.2)          3
  Endocrine                                                                                                                                                                                                                               
   Hot flashes                          2594 (40.1)         16                                                    2789 (40)                                            12                       488 (52.7)         4   3277 (41.9)        16
   Gynecomastia                         1441 (9.4)          10                                                    1987 (7)                                             9                        257 (17.5)         2   2244 (8.2)         11
   Breast tenderness or pain            649 (7.7)           5                                                     1206 (5.1)                                           5                        257 (6.6)          2   1463 (5.4)         7
   Impotence                            515 (71.1)          5                                                     362 (66)                                             4                        156 (82.1)         1   518 (70.8)         5
   Decreased libido                     519 (70.1)          5                                                     367 (65.4)                                           4                        156 (78.8)         1   523 (69.4)         5
  Gastrointestinal ([gi]{.smallcaps})                                                                                                                                                                                                     
   [gi]{.smallcaps}, not specified      959 (2.3)           7                                                     768 (10.3)                                           6                        175 (0.6)          1   943 (8.5)          7
   Nausea or vomiting                   1872 (3.2--7.1)     8                                                     1851 (5.6--9.2)                                      8                        0 (0)              0   1851 (5.6--9.2)    8
   Diarrhea                             1464 (2.2)          6                                                     1458 (8.2)                                           6                        0 (0)              0   1458 (8.2)         6
   [gi]{.smallcaps} pain                124 (1.6)           2                                                     122 (7.4)                                            2                        0 (0)              0   122 (7.4)          2
  Hepatic                                                                                                                                                                                                                                 
   Hepatic, not specified               1197 (1.3)          4                                                     2004 (5)                                             6                        0 (0)              0                      
   Increased liver enzymes              483 (2.7)           3                                                     474 (6.8)                                            3                        0 (0)              0   [nr]{.smallcaps}   
  *Ophthalmologic*                      *Orchiectomy*       *Orchiectomy + nilutamide*                                                                                                                                                    
  Ophthalmologic, not specified         407 (5.4)           3                                                     396 (29)                                             3                        [nr]{.smallcaps}       [nr]{.smallcaps}   

[mab]{.smallcaps} = maximal androgen blockade; [nsaa]{.smallcaps} = nonsteroidal anti-androgen; [cpa]{.smallcaps} = cyproterone acetate; [nr]{.smallcaps} = not reported. Adapted, with permission, from Aronson *et al.*[@b20-co13_3p081], Appendix [ii]{.smallcaps}, Tables [ii]{.smallcaps}-6 to [ii]{.smallcaps}-10.

###### 

Adverse effects leading to withdrawal from treatment, combined results

  *Treatment*                                                                          *Studies (*n*)*   *Treatment group (*n*)*   *Withdrawals from treatment \[*n *(%)\]*
  ------------------------------------------------------------------------------------ ----------------- ------------------------- ------------------------------------------
  Leuprolide (1 daily)                                                                 1                 268                       0 (0)
  Goserelin (3.6, 1-month)                                                             11                1679                      33 (2)
  Goserelin (10.8, 3-month)                                                            2                 77                        1 (1.3)
  Buserelin (0.4)                                                                      1                 72                        3 (4.2)
  Orchiectomy + nilutamide (150)                                                       2                 271                       38 (14)
  Orchiectomy + nilutamide (300)                                                       3                 209                       24 (11.5)
  Orchiectomy + [cpa]{.smallcaps} (150)                                                1                 102                       3 (2.9)
  Orchiectomy + [cpa]{.smallcaps} (300)                                                1                 20                        2 (10)
  Orchiectomy or [lhrh]{.smallcaps} agonist or both                                    28                4275                      82 (1.9)
  Goserelin (3.6, 1-month) + flutamide (750)                                           5                 846                       94 (11.1)
  Orchiectomy or [lhrh]{.smallcaps} agonist + flutamide (750) or both                  9                 2804                      233 (8.3)
  Orchiectomy or [lhrh]{.smallcaps} agonist + bicalutamide (50) or both                1                 401                       41 (10.2)
  Orchiectomy or [lhrh]{.smallcaps} agonist + nilutamide (150 or 300) or both          5                 480                       62 (12.9)
  Orchiectomy or [lhrh]{.smallcaps} agonist + [cpa]{.smallcaps} (150 or 300) or both   2                 122                       5 (4.1)

[cpa]{.smallcaps} = cyproterone acetate; [lhrh]{.smallcaps} = luteinizing hormone--releasing hormone. From Aronson *et al.* [@b20-co13_3p081], Appendix [ii]{.smallcaps}, Table [ii]{.smallcaps}-11. Used with permission.

                                                                                                                                                                            *Meta-analyses*                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ----- ----- ----- ----- -----
  INTRODUCTION                                                                                                                                                                                                        
   Clinical problem                                                                                                                                                         ---               ---   •     •     •     ---
   Biologic rationale for treatment                                                                                                                                         •                 •     •     •     •     •
   Rationale for review                                                                                                                                                     •                 •     •     •     •     •
  METHODS                                                                                                                                                                                                             
   Searching                                                                                                                                                                                                          
    Information sources (e.g., databases, registers)                                                                                                                        ○                 ---   •     •     ---   •
    Restrictions (e.g., years, publication status, language)                                                                                                                ○                 ---   ○     •     ○     •
   Selection                                                                                                                                                                                                          
    Inclusion/exclusion criteria (e.g., defining population, intervention, outcomes, and study design)                                                                      ○                 ○     •     •     ○     •
   Validity assessment                                                                                                                                                                                                
    Criteria and process used (e.g., masked conditions, quality assessment, and their findings)                                                                             ---               ---   •     •     ---   •
   Data abstraction                                                                                                                                                                                                   
    Process used (e.g., completed independently or in duplicate)                                                                                                            ---               ---   •     •     ○     •
   Study characteristics                                                                                                                                                                                              
    Type of study design                                                                                                                                                    •                 •     •     •     ---   ---
    Participants' characteristics                                                                                                                                           ---               •     •     •     ---   ---
    Details of intervention                                                                                                                                                 ---               •     •     •     ---   ---
    Outcome definitions                                                                                                                                                     ---               •     •     •     ○     ---
    How clinical heterogeneity assessed                                                                                                                                     ---               ---   ---   •     ---   ---
   Quantitative data synthesis                                                                                                                                                                                        
    Measures of effect (e.g., relative risk, hazard ratio)                                                                                                                  •                 •     •     •     •     •
    Method of combining results (e.g., statistical testing, [ci]{.smallcaps}s)                                                                                              •                 •     •     •     •     •
    Handling of missing data                                                                                                                                                ---               ---   ---   •     •     •
    How statistical heterogeneity was assessed                                                                                                                              ---               •     •     •     ---   ---
    Rationale for any *a priori* sub-group and sensitivity analyses                                                                                                         ---               ---   •     •     ---   •
    Assessment of publication bias                                                                                                                                          ---               ---   ---   •     ---   ---
  RESULTS                                                                                                                                                                                                             
   Trial flow                                                                                                                                                                                                         
    Provide meta-analysis profile summarizing trial flow                                                                                                                    ---               ---   ---   ---   ---   ---
   Study characteristics                                                                                                                                                                                              
    Present descriptive data for each trial (e.g., age, sample size, intervention, dose, duration, follow-up period)                                                        •                 ---   •     •     •     •
   Quantitative data synthesis                                                                                                                                                                                        
    Report agreement on selection and validity assessment                                                                                                                   ---               ---   •     •     ---   •
    Present summary results (for each treatment group in trial and each outcome)                                                                                            •                 •     •     •     •     ---
    Present data needed to calculate effect sizes and [ci]{.smallcaps}s in [itt]{.smallcaps} analyses (e.g., 2×2 tables of counts, means, proportions, [sd]{.smallcaps}s)   •                 •     •     •     ---   ---
  DISCUSSION                                                                                                                                                                                                          
   Summarize key findings                                                                                                                                                   •                 •     •     •     •     •
   Discuss clinical inferences based on internal and external validity                                                                                                      •                 ○     •     •     •     •
   Interpret results in light of the totality of evidence                                                                                                                   •                 ---   ○     ○     •     •
   Describe potential biases in the review process (e.g., publication bias)                                                                                                 •                 ---   ○     ○     ○     ○
   Suggest future research agenda                                                                                                                                           ---               ---   •     •     ---   ○

[ipd]{.smallcaps} = individual patient data; [pctcg]{.smallcaps} = Prostate Cancer Trialists' Collaborative Group; [ci]{.smallcaps}s = confidence intervals; [itt]{.smallcaps} = intent-to-treat; [sd]{.smallcaps}s = standard deviations.
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